Oncology Xagena
Zoledronic Acid ( Zometa ), an intravenous bisphosphonate, was shown to inhibit aromatase inhibitor-induced bone loss in postmenopausal women treated with Letrozole ( Femara ) in the adjuvant breast c ...
The treatment with Letrozole ( Femara ) of postmenopausal women with early breast cancer prolonged disease-free survival by reducing the risk of recurrence an additional 19% over that offered by Tamox ...
A study, published in The Lancet, demonstrated that switching treatment to the drug Anastrozole ( Arimidex ) after two years of Tamoxifen ( Nolvadex ) can improve event-free survival for postmenopausa ...
The complete analysis of data from a trial of the drug Letrozole ( Femara ) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with Tamoxifen ( ...
Few women with invasive breast cancer who are treated with lumpectomy, radiation and five years of Tamoxifen would benefit from taking an aromatase inhibitor after Tamoxifen. " A randomized study i ...
Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has found that anticancer drugs aren't the only culprits. Among 64 breast c ...
Treatment with the aromatase inhibitor Letrozole ( Femara ) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of Tamoxifen therapy. The results of a ...
Treatment with the aromatase inhibitor Letrozole ( Femara ) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of Tamoxifen therapy. The results of ...
Osteoporosis is a growing concern among breast tumor survivors, because certain cancer drugs can cause bone loss.A new study has found that anticancer drugs aren't the only culprits. Among 64 breast c ...
Two separate meta-analyses of clinical trials that tested Tamoxifen ( Nolvadex ) against aromatase inhibitors in postmenopausal women with early breast cancer have each reached the same conclusion: ar ...
Pfizer has announced its investigational compound Palbociclib ( PD-0332991 ), an oral and selective inhibitor of cyclin-dependent kinases 4 and 6 ( CDK 4/6 inhibitor ), has received Breakthrough Thera ...
Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is debated. Letrozole ( Femara ) has never been tested ...
